Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price In Tune With Revenues
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Barclays analyst Balaji Prasad maintains $Tarsus Pharmaceuticals(TARS.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 44.9%
Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
Earnings Call Summary | Tarsus Pharmaceuticals(TARS.US) Q2 2024 Earnings Conference
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript